Mostrar o rexistro simple do ítem

dc.contributor.authorNúñez, Lucía
dc.contributor.authorCrespo-Leiro, María Generosa
dc.contributor.authorMarrón Liñares, Grecia Manuela
dc.contributor.authorSuárez-Fuentetaja, Natalia
dc.contributor.authorBarge-Caballero, Eduardo
dc.contributor.authorPaniagua-Martín, María J.
dc.contributor.authorMarzoa Rivas, Raquel
dc.contributor.authorGrille Cancela, Zulaika
dc.contributor.authorMuñiz, Javier
dc.contributor.authorVázquez Rodríguez, José Manuel
dc.contributor.authorHermida-Prieto, Manuel
dc.date.accessioned2016-11-14T09:39:58Z
dc.date.available2016-11-14T09:39:58Z
dc.date.issued2016
dc.identifier.citationNúñez L, Crespo-Leiro MG, Marrón-Liñares GM, et al. Analysis of variants in the HCN4 gene and in three single nucleotide polymorphisms of the CYP3A4 gene for association with ivabradine reduction in heart rate: a preliminary report. Cardiol J.2016;23(5):573-582es_ES
dc.identifier.issn1897-5593
dc.identifier.issn1898-018X
dc.identifier.urihttp://hdl.handle.net/2183/17552
dc.description.abstract[Abstract] Background: Ivabradine, a selective bradycardic drug, inhibits the If. In patients with heart failure (HF), ivabradine reduces the risk of rehospitalization and mortality. The average heart rate (HR) reduction is 8–10 beats, although clinical trials reveal interindividual variability. The aim of the study is to identify variants associated with HR reduction produced by ivabradine in genes involved in the drug metabolism (CYP3A4) or related to the drug target (HCN4). Methods: In an exploratory cohort (n = 11), patients started on ivabradine were genotyped and the HR reduction was studied. Results: The mean HR reduction after the treatment was 18.10 ± 12.26 bpm. The HR reduction was ≥ 15 bpm in 3 patients and > 5 and < 15 bpm in 7 patients. Four synonymous variants, L12L, L520L, P852P, and P1200P, were detected in the HCN4 gene (frequency = 0.045, 0.045, and 0.681, respectively). Moreover, the CYP3A4*1F and CYP3A4*1B were found in one patient each and CYP3A4*1G was presented in 3 patients. Conclusions: This is the first study using an exploratory pharmacogenetic approach that attempts to explain interindividual variability in ivabradine HR reduction. However, more research must be undertaken in order to determine the role of variants in HCN4 and CYP3A4 genes in response to ivabradine.es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; RD12/0042es_ES
dc.language.isoenges_ES
dc.publisherVia Médicaes_ES
dc.relation.urihttp://dx.doi.org/10.5603/CJ.a2016.0050es_ES
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Españaes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectHeart failurees_ES
dc.subjectIvabradinees_ES
dc.subjectHCN4es_ES
dc.subjectCYP3A4es_ES
dc.subjectPharmacogenetices_ES
dc.titleAnalysis of variants in the HCN4 gene and in three single nucleotide polymorphisms of the CYP3A4 gene for association with ivabradine reduction in heart rate: a preliminary reportes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/openAccesses_ES
UDC.journalTitleCardiology Journales_ES
UDC.volume23es_ES
UDC.issue5es_ES
UDC.startPage573es_ES
UDC.endPage582es_ES


Ficheiros no ítem

Thumbnail
Thumbnail

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem